VEGFA and edema: In a multicentre randomised clinical trial comparing intravitreal aflibercept, bevacizumab and ranibizumab for vision-impairing centre-involved DMO (DRCR.net protocol T), 31.6% of patients on aflibercept and 41.5% on ranibizumab experienced persistent oedema following 24 weeks of treatment, indicating that non-response to anti-VEGF monotherapy is not uncommon [13].